Dr. Lev Gertsik earned his medical degree in Moscow, Russia. After completing postgraduate psychiatric training, he practiced consultation and liaison psychiatry and psychoanalytic psychotherapy. Dr. Gertsik was a founder and Medical Director of The Moscow Center for Psychoneuroendocrinology, an innovative institution dedicated to diagnosis and treatment of complex cases at the intersection of psychiatric and endocrine disorders and gender identity issues. He had also served as a Medical Director of the Russian Psychoanalytic Association. After moving to the US in 1992, Dr. Gertsik completed both his psychiatry internship and residency at the UCLA San Fernando Valley Program. He had pursued additional studies in mood disorders and psychopharmacology at the UCLA Neuropsychiatric Institute. Dr. Gertsik also completed a psychoanalytic psychotherapy training program at The Southern California Psychoanalytic Institute. Dr. Gertsik is board certified in psychiatry since 2002.
Dr. Gertsik currently serves as the Medical Director of the California Clinical Trials Medical Group, an internationally recognized research organization which has contributed to the development of the many psychotropic agents that are used to treat schizophrenia, mood disorders, and dementia. Dr. Gertsik has been a principal investigator or co-investigator in more than 300 clinical trials, and has published extensively. He has received research funding from the pharmaceutical industry, The National Institute of Health and The NARSAD Foundation. Dr. Gertsik is the Chairman of the Department of Psychiatry at Glendale Adventist Medical Center, and he is on staff of Della Martin Psychiatric Center at Huntington Hospital in Pasadena, CA.